Asciminib in Relapsed Chronic Myeloid Leukemia

To the Editor: Hughes et al. (Dec. 12 issue) 1 report antileukemic activity of asciminib in pretreated patients with chronic myeloid leukemia (CML). A major molecular response was achieved or maintained by 12 months in 28% of the patients (5 of 18) with a T315I mutation at baseline. One of these 5 patients in whom a major molecular response was achieved or maintained by 12 months was 1 of the 5 patients in the study who had ponatinib resistance and a T315I mutation. Although ponatinib is the only tyrosine kinase inhibitor approved by the Food and Drug Administration that has shown . . .